Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. März 2016 09:00 ET | Quelle: Merus N.V.

Merus Announces Issuance of Three U.S. Patents Strengthening Its Biclonics® Technology Platform for the Discovery and Manufacturing of Human Bispecific Antibodies

UTRECHT, The Netherlands, March 09, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the...
04. Januar 2016 07:00 ET | Quelle: Merus N.V.

Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Immuno-Oncology Applications

UTRECHT, The Netherlands and VILLEJUIF, France, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and...
16. Dezember 2015 07:00 ET | Quelle: Merus N.V.

Merus Appoints Hui Liu as Chief Business Officer

Novartis Oncology’s Former Global Head of Business Development and Licensing Joins Immuno-oncology Biotech Company UTRECHT, The Netherlands, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Merus B.V., a...
03. November 2015 14:48 ET | Quelle: Merus N.V.

Merus Announces Final Ruling in Inequitable Conduct Case Against Regeneron

UTRECHT, The Netherlands, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the U.S....